Membership Update – April/May 2013

BioNJ welcomes Drinker Biddle & Reath as a new Platinum Member for 2013.

Drinker Biddle & Reath, LLP Drinker Biddle & Reath’s Life Sciences Group is built from our interdisciplinary practice groups, and comprised of attorneys who have experience, knowledge, and insights about navigating the fast-paced, heavily regulated environment that surrounds scientific research, life-sciences product development, intellectual property protection, employment issues and litigation, product marketing and sales, and health care delivery. We support our Life Sciences clients on issues relating to business and financing pressures, regulatory scrutiny, workforce management and litigation threats. We strive to provide collaborative and strategic advice and value the opportunity to partner with our clients in facing their business and legal challenges.

BioNJ welcomes ATNT, Fluimetrics, Inc., Photocure and Taiho Pharma USA, as Core Members for 2013.

ATNT ATNT is a biotechnology company founded in 2008 and its main focus is on Research and Development. The company is working on the development of several patents. The major focus of ATNT is on target discovery and the development of small molecules for treatment of different solid tumors and a few CNS indications.

Fluimetrics, Inc. Fluimetrics is positioned to leverage the increasing trend toward point-of-use diagnostics with its automated immunoassay platform. Using a unique technology developed at Rutgers University, the Fluimetrics system is a universal automation platform for all immunoassays. Our technology has a strong advantage over competing technologies because there is no need to alter laboratory-developed reagents for our platform; the standard reagents simply drop in. Our products will provide sample-to-answer results in about 20 minutes with high sensitivity, while detecting multiple analytes in a sample.

Photocure Photocure ASA, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology™ platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Photocure is listed on the Oslo Stock Exchange (OSE: PHO).

1

Hexvix is the first approved drug-device combination procedure for improved detection and management of bladder cancer. It is designed to induce fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect non muscle invasive bladder cancer, as an adjunct to white light cystoscopy. It is the first product in a new diagnostic class known as Photodynamic Diagnostic (PDD) agents. Photocure markets and sells Cysview directly in the US. Information about Photocure is available at www.photocure.com.

Taiho Pharma USA, Inc. (TPUI) Taiho Pharma USA, Inc. (TPUI), with headquarters in Princeton, NJ, is a subsidiary of Taiho Pharmaceutical Company, LTD (TPC). TPC was established in Japan as a member of the Otsuka Group in 1963. TPC is a leading provider of pharmaceutical and OTC products in Japan. TPC is focused on simultaneous global development of the numerous agents in our pipeline, aiming to get those new drugs to patients around the world as soon as possible. TPC has an extraordinary pipeline of eight oral ant-cancer agents in development that are in the pre- clinical to Phase III stage. Taiho Pharmaceutical’s globalization plan includes becoming a fully integrated development and commercial organization in the U.S. and Europe. In that process, the most important thing will be securing, training, and properly deploying people with great talent from diverse backgrounds. For additional information please visit our web site: http://taiho-oncology.com/index.php.

BioNJ welcomes Advanced Bioscience Laboratories, Ambrose Employer Group, Blinded Diagnostics, Diamond Law Office, JBK Associates, Linde LLC and Multinational Partnerships as new Associate Members for 2013.

Advanced Bioscience Laboratories, Inc. ABL is a CRO and CMO with over 50 years of experience working with clients to meet their preclinical product development goals. Through effective partnerships, ABL investigators have played key roles in advancing the field of immunological and virological research. A full range of in vivo and in vitro testing services coupled with cGMP biologics manufacturing enables ABL to accelerate candidate vaccines and biotherapeutics into the clinic. ABL provides integrated product development services for industry, academia, and government clients on indications spanning from infectious disease to heart disease.

Ambrose Employer Group, LLC Founded in 1997, Ambrose is a Professional Employer Organization (PEO) that provides an outsourced human resources, payroll, and employee benefits solution tailored to the needs of biotechnology, technology, and professional services firms. With the help of Ambrose, over 900 great small businesses have been able to free resources to focus on their core activities. Ambrose was ranked by Crain's New York as one of the 50 fastest growing companies. Crain’s New York covers NYC's major industries, including Wall Street, media, the arts, real estate, retail, restaurants and more. Ambrose was also ranked by the Society for Human Resource Management as one of the "Best Companies to Work For" for the second consecutive year. For additional information, please visit www.ambrose.com .

Blinded Diagnostics Recent advancements in microfluidics and biosensor technology now means that we are able to identify, and provide delivery of, innovative technology to conduct over 120 different vital diagnostic tests and capture critical performance metrics for Phase 1-4 clinical research

2 programs. Our scope of business includes integral involvement in clinical trial protocol development and ascertaining that study objectives will be successfully supported by trial design. By utilizing the optimal selection of Point-of-Care Testing equipment, the pharmaceutical researchers that we work with can achieve overall cost and time savings. Furthermore, in studies involving study drug dose-adjustment based upon critical diagnostic information, the strategy that we construct provides a near-immediate delivery of the requisite key metrics, providing the ability to rapidly administer a dosage that is closely matched to the patient’s status.

Through the use of proprietary methodologies, we can produce firmware encryption of the diagnostic output of the Point-of-Care Testing devices – so that the study physician is not obviously made aware of the patient’s specific diagnostic reading, and thus enabling the preservation of the integrity of the “double blinded” nature of specific clinical studies. This is the inspiration for our name “Blinded Diagnostics”.

We are also working on an initiative to create a system to achieve secured electronic data transfer for all configurations of Point-of-Care Testing devices and all instances of Point-of-Care device deployment. This will reduce paperwork related data discrepancies and facilitate direct delivery of clinical site information into the Electronic Data Capture (EDC) system.

Diamond Law Office, LLC Diamond Law Office, LLC is a New Jersey-based patent law firm focusing on the life sciences. Principal attorney, Paul Diamond, Ph.D., Esq., brings over twelve years of legal experience in the fields of biotechnology, pharmaceuticals and medical devices to his practice. The firm's commitment is to provide sophisticated, yet affordable, patent legal representation while maintaining close personal attention to its clients' matters.

JBK Associates JBK Associates, Inc. is a retainer-based, award-winning and woman-owned certified executive search firm with a strong focus on the life science and healthcare industries. Placing super-star talent in a wide array of functional specialties, JBK Associates, an AESC member, takes a fully- integrated talent management approach to help all size organizations achieve major growth by providing best-in-class solutions for search, staffing and organizational development. The firm has been recognized by Forbes, The American Business Awards, Diversity Business, Working Mother, Pharma Voice and New Jersey Business for its achievements and track record of success.

Linde LLC Linde LLC (formerly BOC Gases), one of the world’s largest supplier of bulk industrial gases, is proud to have been chosen as the exclusive Primary Supplier of Pharma & Biotech Gases for the BIO Association. Linde is your source for Liquid Bulk Products, Liquid Cylinders & Dewars, and Gaseous Tube Trailers. In the United States, Linde operates 33 Air Separation plants (Nitrogen, Oxygen, and Argon), 12 helium facilities and 23 carbon dioxide plants, all delivered with world class logistics. In addition to our contracted gas supply rebates (exclusive to BIO members), we provide a variety of applications technologies to assist customers in Pharmaceutical and Biotech Manufacturing and Research, Medical Research and Clinical Applications, Energy, and Chemicals with:

 Low temperature reaction cooling, & Lyophilization  Vapor emissions control and re-capture

3

 Cryo-cleaning processes (non-abrasive, chemical-free, no rinsing, quicker cleanup time)

Multinational Partnerships LLC We are a US consulting company for life science businesses, with a focus on business expansion across the Latin American markets, and the development and management of business alliances among multinational and Latin American organizations.

 Multinational Partnerships is an organization with a worldwide network of experts in diverse areas of life-science and with real hands-on experience in Latin American markets.  Multinational Partnerships was conceived as an international endeavor with a global mindset and a desire to serve companies looking to operate in Latin American markets.  Multinational Partnerships’ experienced team has in-depth expertise in business and governance consultancy, technology transfer, project management and due diligence services, gained in diverse corporate environments.

Multinational Partnerships operates regionally from North America and locally within Latin American countries.

BioNJ thanks Campbell Alliance, Fisher Scientific and United Parcel Service for renewing as Platinum Members for 2013.

Campbell Alliance Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm’s clients include most of the world’s top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales. From its locations in Raleigh, NC, Parsippany, NJ, , San Francisco, Chicago, , Philadelphia, , , and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

Fisher Scientific Fisher Scientific specializes in scientific research, laboratory testing and life science research, providing the latest equipment and instrumentation, finest chemicals and highest-quality supplies. We are also a full-service provider of leading-edge safety products, training, equipment maintenance and procurement solutions for industrial, laboratory safety and first responder customers. We service the nation's diagnostic testing needs in hospitals, reference labs and physician's office laboratories with more offerings, more solutions and more value. Fisher Scientific also provides resources for educators to create scientific excitement in elementary, secondary and college classrooms with essential products and invaluable information.

United Parcel Service UPS is a global leader in logistics, offering a broad range of solutions including the transportation of packages and freight; the facilitation of international trade, and the deployment of advanced technology to more efficiently manage the world of business. For the healthcare industry, UPS is equipped with specialized capabilities ranging from temperature-controlled

4 warehousing and transportation services, to regulatory compliance expertise and sophisticated monitoring technology. For information about UPS's healthcare services, visit: ups.com/healthcare.

BioNJ thanks AlfaGene Bioscience, Cancer Genetics, Cyclacel Pharmaceuticals, Edge Therapeutics, ShanghaiBio Corporation, Signum Biosciences, Soligenix, TAXIS Pharmaceuticals and Thymon for renewing as Core Members for 2013.

AlfaGene Bioscience AlfaGene Bioscience is a prime source of genomics and proteomics products for biopharmaceutical industries and research institutions. The company can give expert advice and customized services to fit any client’s project needs, from library construction and gene identification to protein expression and purification.

Cancer Genetics, Inc. Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. Products and services being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state- of-the-art reference laboratory provide critical genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.

CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and CAP accredited, In addition we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey. Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti.

CGI’s scientific advisory board includes leading specialists in clinical cytogenetics, as well as significant thought leaders capable of driving adoption in the tri-state area. The company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, as well as strong academic relationships with major cancer centers such as Memorial Sloan-Kettering and the National Cancer Institute. CGI’s full-service cancer genetic practice and path to innovation with research makes for optimal patient care management.

Cyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel drugs to treat human cancers and other serious disorders. The Company’s strategy is to build a diversified biopharmaceutical business based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Edge Therapeutics, Inc. Edge Therapeutics uses a novel, site-specific and sustained release-microparticle technology platform to deliver drugs to the brain and treat acute, and fatal or debilitating neurological conditions that currently have no effective therapies. Edge works with some of the world’s foremost scientists from leading academic research centers to develop proprietary and novel formulations of known active drugs for direct therapeutic delivery to the site of injury in the brain.

5

ShanghaiBio Corporation ShanghaiBio Corporation is a leading biotech with lab operations in Shanghai, China and New Jersey in the U.S. ShanghaiBio performs total genomics solution services for translational medicine focusing on biobanking, Microarray, Next Generation Sequencing (NGS), and biomarker assay development and companion diagnostics for personalized medicine. ShanghaiBio has been providing quality services for most of the top 20 global pharmaceutical firms, global CROs and biotech companies, and top research institutes in China around the world for the past decade. They support translational research, biomarker development, and clinical trials for personalized medicine.

Signum Biosciences, Inc. Signum Biosciences is a private biotechnology company dedicated to developing small- molecule therapeutics derived from our phosphatase platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's, and other neurodegenerative diseases. Signum's phosphatase technology provides many opportunities for the development of novel pharmaceutical therapeutics.

Soligenix, Inc. Soligenix, Inc., formerly known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix’s lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD.

TAXIS Pharmaceuticals TAXIS, a Delaware-based subchapter S corporation with operations in New Jersey, was formed in March, 2009 by the two scientific founders - Ed LaVoie, Chair of the Department of Medicinal Chemistry, Rutgers and Dani Pilch, Associate Professor of Pharmacology, UMDNJ - and the chief executive officer, Gregory G. Mario. TAXIS is focusing its current efforts on developing the azachryseniums (AZCs) as a novel class of bactericidal agents that can effectively treat infections caused by MDR bacterial pathogens.

Thymon, LLC Thymon, LLC, founded in 1996 by Dr. Gideon Goldstein, functions as a virtual company with all laboratory and clinical studies directed and funded internally but performed externally by contracted organizations.

The company is the assignee of seven issued Goldstein patents covering a synthetic universal HIV-1 Tat epitope vaccine (TUTI-16) and a human monoclonal antibody (tepiumab) universally reactive with HIV-1 Tat protein.

HIV-1 Tat protein is essential for maintenance of HIV set point viremia and an exploratory randomized, placebo-controlled study of TUTI-16 in untreated HIV infected subjects yielded a highly significant reduction in viral load following immunization.

This study supported the feasibility of TUTI-16 as a potential prophylactic and therapeutic HIV/AIDS vaccine and the feasibility of tepiumab for antiretroviral treatment.

6

Thymon will be seeking licensing partner(s) as these projects move towards BLA studies and commercialization.

BioNJ thanks BioConsulting International, HCRAmerica, JFK Communications and Provonix for renewing as Associate Members for 2013.

BioConsulting International, LLC BioConsulting International, LLC (BCI) is well-positioned to provide your organization with practical answers to the myriad of complex problems that arise in life science, in vitro diagnostic and biotech business operations during periods of rapid growth. Whether those problems or challenges present themselves in the Development, Manufacturing or Quality facets of a project or whether external factors may be in play, the sole focus of our service is to quickly assess the particular client business situation, recommend immediate and mid-term solutions that are custom-fit to the organization’s capabilities. We work with small and medium-sized firms on a variety of projects that span a range of operational, technical and compliance-based issues. BCI provides a unique and focused set of capabilities tailored for the life science or IVD client who is looking to start or build-up their business and who prefer to work with a small, focused and experienced consulting entity to achieve their goals. BCI operates primarily on a project fee consulting basis but arrangements can also be developed to include retainer, per-diem or hourly based consults. We seek to provide the most flexible arrangement that is customized to effectively deliver the results required for each client and project.

HCRAmerica, LLC HCRAmerica is a full-service, scientifically driven, Phase I-IV CRO based in Princeton and an affiliate of Harrison Clinical Research, GmbH, a global CRO with offices worldwide. Dr. Michael Willett, President of HCR America, brings a 20-year record as a successful senior executive, clinical scientist and regulatory strategist. HCRAmerica is proud to be a member of BioNJ.

JFK Communications Inc. JFK Communications is a healthcare public relations firm that partners with specialty pharmaceutical, biotechnology and medical technology companies. If you need a strategic communications firm whose knowledge is exceeded only by its passion, we’re ready to help.

Provonix Provonix is a Contract Research Organization specializing in analyzing and reporting clinical trial data. We have worked in many therapeutic areas, for all phases of trials, and have significant experience in setting up and conducting clinical trials. It is our attention to detail and expertise in statistical planning, analysis, programming and reporting that set us apart from other CROs.

Provonix offers individualized, affordable clinical trial support. Specifically, the services we provide are: Biostatistical Consulting, SAS programming, Data Management, Medical Writing and Pharmacokinetic Analysis.

We are located in the Rohrer College of Business Incubator at Rowan University, in Glassboro, NJ.

7

BioNJ thanks InspireMD for renewing as an International Member for 2013.

InspireMD InspireMD, Inc. is a high growth medical device company focusing on the development and commercialization of its proprietary stent platform technology: MGuard™. InspireMD has created a unique, patent-pending mesh net technology that wraps a stent, providing embolic protection (preventing Major Adverse Cardiac Events (MACE) by filtering debris) and reducing vessel injury by spreading strut pressure. MGuard™ is delivered with no change to the current procedure and is well-accepted by physicians. MGuard™ has been implanted in thousands of patients, and in clinical trials it has shown a more than 50 percent reduction in MACE compared with traditional bare metal stents.

MGuard™ is the only complete solution for high-risk Acute Coronary Syndrome (heart attack) patients — a market of over two million patients per year. This market is the fastest-growing segment of the stent market, currently estimated to exceed $2.3 billion annually with limited competition for InspireMD. MGuard™ and the next generation MGuard Prime™ have distribution agreements in more than 40 territories, including Europe, Asia, Australia, Brazil, the Far East, India, and South America. In two years, InspireMD has ramped from $0 in revenue to $5 million annually and is experiencing ongoing rapid growth.

The Company is seeking FDA approval to sell in the United States, and is collaborating with the Harvard Clinical Research Institute (HCRI), an international leader in design and conduct of coronary device trials, for U.S. FDA trials.

BioNJ thanks UK Trade & Investment for renewing as an Institutional Member for 2013.

UK Trade & Investment (UKTI) UK Trade & Investment (UKTI) is the commercial arm of the British government. We help UK companies expand abroad and work with U.S. companies that are looking to set up or grow businesses in the UK/EU. Please get in touch if you’d like free information on R&D, clinical trials, commercial or funding opportunities in the UK.

CLICK HERE to return to the main page.

8